Tag: compensation

Not for distribution to U.S. newswire services or for dissemination in the United States.

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts (“ADRs”) of Immutep Ltd. (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026, inclusive (the “Class Period”), of the important July 6, 2026 lead plaintiff deadline.

ATN received $268 million in cash proceeds upon initial closing

ATLANTA, June 02, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced that it completed its acquisition of Family First Holding, LLC ("Family First Homecare").

Press Release

NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Globant S.A. (NYSE: GLOB) between February 15, 2024 and August 14, 2025, inclusive (the “Class Period”), of the important June 23, 2026 lead plaintiff deadline.

NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock on the New York Stock Exchange (“NYSE”) of Stellantis N.V. (NYSE: STLA) between February 26, 2025 and February 5, 2026, inclusive (the “Class Period”), of the important June 8, 2026 lead plaintiff deadline.

NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of AeroVironment, Inc. (NASDAQ: AVAV) between June 25, 2025 and March 10, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 27, 2026.

BOSTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on June 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 61,050 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 12,900 shares of Vor Bio’s common stock to 10 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).